(3r,4s)-rel-1-哌啶羧酸,3-氨基-4-甲基-,1,1-二甲基乙酯 | 1271810-27-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: (3r,4s)-rel-1-哌啶羧酸,3-氨基-4-甲基-,1,1-二甲基乙酯
• 英文名称: (3S,4R)-3-amino-4-methylpiperidinyl-1-carboxylic acid tert-butyl ester
• 英文别名: (3S,4R)-tert-Butyl 3-amino-4-methylpiperidine-1-carboxylate；tert-butyl (3S,4R)-3-amino-4-methylpiperidine-1-carboxylate
• CAS: 1271810-27-5
• 化学式: C₁₁H₂₂N₂O₂
• 分子量: 214.308
• InChiKey: OWWPBKGSGNQMPL-RKDXNWHRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  (3S,4R)-3-hydrazino-4-methylpiperidinyl-1-carboxylic acid tert-butyl ester 在 氢气 作用下， 以 甲醇 为溶剂， 20.0~30.0 ℃ 、101.33 kPa 条件下， 反应 24.0h， 以50%的产率得到(3r,4s)-rel-1-哌啶羧酸,3-氨基-4-甲基-,1,1-二甲基乙酯
  参考文献：
  名称：

  CN103664743

  摘要：

  公开号：

文献信息

• [EN] HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES POUR LE TRAITEMENT D'UNE PROLIFÉRATION CELLULAIRE ANORMALE
  申请人：G1 THERAPEUTICS INC

  公开号：WO2019136244A1

  公开（公告）日：2019-07-11

  This invention is in the area of heterocyclic-based compounds for the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.

  这项发明涉及杂环基化合物领域，用于治疗涉及异常细胞增殖的疾病，包括但不限于肿瘤和癌症。
• Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating IRE1-related diseases and disorders
  申请人：Genentech, Inc.

  公开号：US10968203B2

  公开（公告）日：2021-04-06

  Described herein are pyrimidinyl-pyridyloxy-naphthyl compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I or I′ structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I or I′ compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

  这里描述的是具有式 I 或 I′结构的嘧啶基吡啶氧基萘化合物，它们具有调节肌醇需要酶 1（IRE1）的活性或功能： 或其立体异构体、同系物或药学上可接受的盐，并具有本文所述的取代基和结构特征。还描述了包括式Ⅰ或Ⅰ′化合物的药物组合物和药物，以及单独或与其它治疗剂联合使用这种IRE1调节剂治疗由雌激素受体介导或依赖于雌激素受体的疾病或病症的方法。
• PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE
  申请人：CANCER RESEARCH TECHNOLOGY LIMITED

  公开号：US20160362410A1

  公开（公告）日：2016-12-15

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds (referred to herein as “PPDA compounds”) that, inter alia, inhibit (e.g., selectively inhibit) CDK (e.g., CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, CDK13, etc.). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CDK; and to treat disorders including: disorders that are associated with CDK; disorders that result from an inappropriate activity of a cyclin-dependent kinase (CDK); disorders that are associated with CDK mutation; disorders that are associated with CDK overexpression; disorders that are associated with upstream pathway activation of CDK; disorders that are ameliorated by the inhibition of CDK; proliferative disorders; cancer; viral infections (including HIV); neurodegenerative disorders (including Alzheimer's disease and Parkinson's disease); ischaemia; renal diseases; and cardiovascular disorders (including atherosclerosis). Optionally, the treatment further comprises treatment (e.g., simultaneous or sequential treatment) with a further active agent which is, e.g., an aromatase inhibitor, an anti-estrogen, a Her2 blocker, a cytotoxic chemotherapeutic agent, etc.
• HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION
  申请人：G1 Therapeutics, Inc.

  公开号：US20200331925A1

  公开（公告）日：2020-10-22

  This invention is in the area of heterocyclic-based compounds for the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.
• US9932344B2
  申请人：——

  公开号：US9932344B2

  公开（公告）日：2018-04-03